•  Summary 
  •  Actions 
  •  Committee Votes 
  •  Floor Votes 
  •  Memo 
  •  Text 
  •  LFIN 
  •  Chamber Video/Transcript 

S06092 Summary:

Amd §3360, Pub Health L
Amends the dosing limitations and medical conditions permitting the use of medical marihuana.
Go to top    

S06092 Actions:

Go to top

S06092 Text:

                STATE OF NEW YORK
                               2017-2018 Regular Sessions
                    IN SENATE
                                      May 11, 2017
        Introduced  by  Sen.  SAVINO -- read twice and ordered printed, and when
          printed to be committed to the Committee on Health
        AN ACT to amend the public health law, in relation to dosing limitations
          and medical conditions permitting the medical use of marihuana
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
     1    Section 1. Subdivision 15 of section 3360 of the public health law, as
     2  added by chapter 90 of the laws of 2014, is amended to read as follows:
     3    15.  "Individual dose" means a single measure of raw medical marihuana
     4  or non-infused concentrates to be determined and clearly identified by a
     5  patient's practitioner for the patient's specific  certified  condition.
     6  [For ingestible or sub-lingual medical marihuana products, no individual
     7  dose may contain more than ten milligrams of tetrahydrocannabinol.]
     8    §  2. Subdivision 7 of section 3360 of the public health law, as added
     9  by chapter 90 of the laws of 2014, is amended to read as follows:
    10    7. [(a)] "Serious condition" means:
    11    (i) having one of the following severe debilitating or  life-threaten-
    12  ing conditions: cancer, positive status for human immunodeficiency virus
    13  or  acquired  immune deficiency syndrome, amyotrophic lateral sclerosis,
    14  Alzheimer's  disease,  traumatic  brain  injury,  dystonia,  Parkinson's
    15  disease,  multiple  sclerosis, muscular dystrophy, damage to the nervous
    16  tissue of the spinal cord  with  objective  neurological  indication  of
    17  intractable  spasticity,  epilepsy,  wasting  syndrome,  post  traumatic
    18  stress  disorder,  rheumatoid  arthritis,  lupus,   inflammatory   bowel
    19  disease,  neuropathies, Huntington's disease, or as added by the commis-
    20  sioner; [and] or
    21    (ii) any of the following conditions where it is clinically associated
    22  with, or a complication of, a condition  under  this  paragraph  or  its
    23  treatment:  cachexia or wasting syndrome; severe or chronic pain; severe
    24  nausea; seizures; severe or persistent muscle spasms; or such conditions
    25  as are added by the commissioner.
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.

        S. 6092                             2
     1    [(b) No later than eighteen months from the  effective  date  of  this
     2  section,  the  commissioner shall determine whether to add the following
     3  serious conditions: Alzheimer's,  muscular  dystrophy,  dystonia,  post-
     4  traumatic stress disorder and rheumatoid arthritis.]
     5    §  3. This act shall take effect immediately; provided that the amend-
     6  ments to title 5-a of article 33 of the public health law made  by  this
     7  act  shall  not  affect  the  repeal  of  such title and shall be deemed
     8  repealed therewith.
Go to top